found that NSCLC patients with more baseline cellular modules consisting of PDCD1+ CXCL13+ activated T cells, SPP1+ macrophages, and IgG+ plasma cells have better responses to PD‐(L)1 blockades.[23]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.